Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo- controlled, phase 3 trial (sept, 2022)
The Lancet Infectious Diseases（2022）
摘要
Janssen Research & Development.
更多查看译文
关键词
booster regimen,immunogenicity,double-blind,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要